Skip to main content

Showing Efficacy in Treating Rare Pediatric Tumors: Introduction to European Regulatory and Scientific Support Available to Investigators

  • Chapter
  • First Online:
Rare Tumors In Children and Adolescents

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1204 Accesses


How to show in a convincing manner efficacy in the treatment of rare tumors and to advance treatment outcomes is a perpetual challenge to all stakeholders developing new medicinal products. Making pediatric anti-cancer medicines available to treat rare tumors is an important example of the public health agenda of the European Medicines Agency, as sadly, the much-quoted successes in treating some pediatric malignant diseases do not provide a fair representation of the outcomes of any such disease. In this context, stakeholders include pharmaceutical companies that are the developers and practically sole sources of new medicines, and academic researchers who may also be the treating physicians and who drive disease-specific iterative processes to improve cure. This chapter introduces the relevant scientific-regulatory guidelines, followed by a presentation of the principles and experience obtained in orphan medicine designations, to academic researchers as they contribute to medicinal product development. Then, this chapter presents available incentives and opportunities for scientific-regulatory interactions, aspects of trial conduct for the demonstration of efficacy, and finally, considerations on a lack of efficacy of a medicine in treating a rare tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others


  1. 1.

  2. 2.

  3. 3.

  4. 4.

  5. 5.­regulation/document_listing/document_listing_000293.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac0580025b91

  6. 6.

  7. 7.

  8. 8.

    Developing Products for Rare Diseases & Conditions.

  9. 9.

    Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Official Journal of The European Communities.

  10. 10.

  11. 11.

  12. 12.

  13. 13.


  14. 14.

  15. 15.

  16. 16.

  17. 17.


Download references


The views expressed in this chapter are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ralf Herold .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Herold, R., Llinares, J. (2012). Showing Efficacy in Treating Rare Pediatric Tumors: Introduction to European Regulatory and Scientific Support Available to Investigators. In: Schneider, D., Brecht, I., Olson, T., Ferrari, A. (eds) Rare Tumors In Children and Adolescents. Pediatric Oncology. Springer, Berlin, Heidelberg.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04196-9

  • Online ISBN: 978-3-642-04197-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics